TopoTarget completes the capital increase and the acquisition of Apoxis SA
TopoTarget A/S announced the completion of the acquisition of Apoxis SA with 3,598,030 shares having been issued to the vendors of Apoxis. Hereby TopoTarget gains two oncology products to its pipeline. Consistent with the growth strategy pursued by TopoTarget, the acquisition of the Swiss biotech company Apoxis SA shall consolidate two emerging European oncology companies.
The two lead oncology products being developed by Apoxis are: APO010, a human FAS-ligand protein product generated via Apoxis' MegaLigandTM proprietary protein research technology platform in Phase I, and APO866, a small molecule therapeutic inhibiting the NAD+ production.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

3D-printed pills with desired drug release – a step upwards in medication - Funny looking pills are not a design gimmick, they can release medication in a desired time regime!
Alzheimer Forschung Initiative e.V. - Düsseldorf, Germany
Category:Molecular_biology_organizations

Restoring tissue with inspiration from plants and animals
Category:Bacillales
Researchers successfully develop animal free methods for testing chemical compounds for allergens - EU-funded research project developing in vitro test strategies to reduce or replace animal testing use gene expression analysis software

Chemical evolution in a tiny Gulf Stream

Six companies enter BioInnovation Institute's Venture House program receiving additional financial support

Peanut Allergy Prevention: Researchers Uncover Groundbreaking Solution
Hepatoerythropoietic_porphyria
Yerkes_National_Primate_Research_Center
